| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Molecular and Cellular Biology [J. A. T., S. J. M., T. D. D., D. R. R.] and Pathology [G. E. A.], Baylor College of Medicine, Houston, Texas 77030
Reactive stroma has been reported in many cancers, including breast, colon,and prostate. Although changes in stromal cell phenotype and extracellular matrix have been reported, specific mechanisms of how reactive stroma affects tumor progression are not understood. To address the role of stromal cells in differential regulation of tumor incidence, growth rate, and angiogenesis, LNCaP xenograft tumors were constructed in nude mice with five different human prostate stromal cell lines as well as GeneSwitch-3T3 cells engineered to express lacZ under mifepristone regulation. Alone, LNCaP prostate carcinoma cells were essentially nontumorigenic, whereas combinations of LNCaP cells with three different human prostate stromal cell lines (L/S tumors) resulted in a tumor incidence (50–63%) similar to that of control LNCaP plus Matrigel (L/M) tumors over a 9-week period. In contrast, LNCaP combinations with two other human prostate stromal cell lines were nontumorigenic, illustrating that stromal cell effects are differential. L/S tumors exhibited well-developed blood vessels at 2 weeks, whereas control L/M tumors were avascular at 2 weeks and exhibited blood lakes in lieu of extensive vessels at later time points. Xenografts constructed under three-way conditions (LNCaP, Matrigel, and stromal cells; L/M/S tumors) exhibited a 100% tumor incidence and showed rapid blood vessel formation as early as day 7 with mature vessels formed by day 10. L/M/S tumors exhibited a 10.3-fold increase in microvessel density, and the corresponding hemoglobin:tumor weight ratio was increased 2-fold relative to L/M control tumors at day 10. L/M/S tumor wet weight and volume increased by 1.6- and 2.4-fold, respectively, by day 21, compared with control L/M tumors. L/M/S tumors made with LNCaP cells plus GeneSwitch-3T3-pGene/lacZ stromal cells showed similar results. Mifepristone-regulated gene expression was observed in stromal cells immediately adjacent to clusters of carcinoma cells and in vessel walls in a mural cell (pericyte) position. This study shows that regulation of angiogenesis is one mechanism through which stromal cells affect LNCaP tumor incidence and growth rate. This regulation may be mediated through direct recruitment and interactions of stromal cells with endothelial cells. Furthermore, this study describes for the first time a model system with regulated transgene expression in the stromal compartment of an experimental carcinoma. These findings point to the stromal compartment as a potential source of new prognostic markers and therapeutic targets and show the utility of the carcinoma-stromal xenograft model system in dissecting specific mechanisms of reactive stroma.
This article has been cited by other articles:
|
|
 |
|
  O. Dakhova, M. Ozen, C. J. Creighton, R. Li, G. Ayala, D. Rowley, and M. Ittmann Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3979 - 3989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ishii, T. Imamura, K. Iguchi, S. Arase, Y. Yoshio, K. Arima, K. Hirano, and Y. Sugimura Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo Endocr. Relat. Cancer, June 1, 2009; 16(2): 415 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Augsten, C. Hagglof, E. Olsson, C. Stolz, P. Tsagozis, T. Levchenko, M. J. Frederick, A. Borg, P. Micke, L. Egevad, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth PNAS, March 3, 2009; 106(9): 3414 - 3419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Hwang, T. Moore, T. Arumugam, V. Ramachandran, K. D. Amos, A. Rivera, B. Ji, D. B. Evans, and C. D. Logsdon Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression Cancer Res., February 1, 2008; 68(3): 918 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Granot, Y. Addadi, V. Kalchenko, A. Harmelin, L. A. Kunz-Schughart, and M. Neeman In vivo Imaging of the Systemic Recruitment of Fibroblasts to the Angiogenic Rim of Ovarian Carcinoma Tumors Cancer Res., October 1, 2007; 67(19): 9180 - 9189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ricciardelli, D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley, and D. J. Horsfall Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility J. Biol. Chem., April 6, 2007; 282(14): 10814 - 10825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bruno, B. Bussolati, C. Grange, F. Collino, M. E. Graziano, U. Ferrando, and G. Camussi CD133+ Renal Progenitor Cells Contribute to Tumor Angiogenesis Am. J. Pathol., December 1, 2006; 169(6): 2223 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
|
|
M. L. Cher, D. A. Towler, S. Rafii, D. Rowley, H. J. Donahue, E. Keller, M. Herlyn, E. A. Cho, and L. W.K. Chung Cancer Interaction with the Bone Microenvironment: A Workshop of the National Institutes of Health Tumor Microenvironment Study Section Am. J. Pathol., May 1, 2006; 168(5): 1405 - 1412. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hanson, J. W. Gillespie, A. Grover, M. A. Tangrea, R. F. Chuaqui, M. R. Emmert-Buck, J. A. Tangrea, S. K. Libutti, W. M. Linehan, and K. G. Woodson Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst, February 15, 2006; 98(4): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rennebeck, M. Martelli, and N. Kyprianou Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis? Cancer Res., December 15, 2005; 65(24): 11230 - 11235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Uemura, H. Ishiguro, Y. Nagashima, T. Sasaki, N. Nakaigawa, H. Hasumi, S. Kato, and Y. Kubota Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells Mol. Cancer Ther., November 1, 2005; 4(11): 1699 - 1709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galie, C. Sorrentino, M. Montani, L. Micossi, E. Di Carlo, T. D'Antuono, L. Calderan, P. Marzola, D. Benati, F. Merigo, et al. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells Carcinogenesis, November 1, 2005; 26(11): 1868 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Yang, J. A. Tuxhorn, S. J. Ressler, S. J. McAlhany, T. D. Dang, and D. R. Rowley Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis Cancer Res., October 1, 2005; 65(19): 8887 - 8895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hagisawa, C. Ohyama, T. Takahashi, M. Endoh, T. Moriya, J. Nakayama, Y. Arai, and M. Fukuda Expression of core 2 {beta}1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression Glycobiology, October 1, 2005; 15(10): 1016 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, C. Zhong, B. Frenkel, A. H. Reddi, and P. Roy-Burman Diverse Biological Effect and Smad Signaling of Bone Morphogenetic Protein 7 in Prostate Tumor Cells Cancer Res., July 1, 2005; 65(13): 5769 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiaris, I. Chatzistamou, G. Trimis, M. Frangou-Plemmenou, A. Pafiti-Kondi, and A. Kalofoutis Evidence for Nonautonomous Effect of p53 Tumor Suppressor in Carcinogenesis Cancer Res., March 1, 2005; 65(5): 1627 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crescioli, A. Morelli, L. Adorini, P. Ferruzzi, M. Luconi, G. B. Vannelli, M. Marini, S. Gelmini, B. Fibbi, S. Donati, et al. Human Bladder as a Novel Target for Vitamin D Receptor Ligands J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 962 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Sis, S Sarioglu, S Sokmen, M Sakar, A Kupelioglu, and M Fuzun Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma J. Clin. Pathol., January 1, 2005; 58(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sivashanmugam, L. Tang, and Y. Daaka Interleukin 6 Mediates the Lysophosphatidic Acid-regulated Cross-talk between Stromal and Epithelial Prostate Cancer Cells J. Biol. Chem., May 14, 2004; 279(20): 21154 - 21159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gray, W. J. Huss, J. M. Yau, L. E. Durham, E. S. Werdin, W. K. Funkhouser Jr., and G. J. Smith Short-Term Human Prostate Primary Xenografts: An in Vivo Model of Human Prostate Cancer Vasculature and Angiogenesis Cancer Res., March 1, 2004; 64(5): 1712 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Walter-Yohrling, X. Cao, M. Callahan, W. Weber, S. Morgenbesser, S. L. Madden, C. Wang, and B. A. Teicher Identification of Genes Expressed in Malignant Cells That Promote Invasion Cancer Res., December 15, 2003; 63(24): 8939 - 8947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ayala, J. A. Tuxhorn, T. M. Wheeler, A. Frolov, P. T. Scardino, M. Ohori, M. Wheeler, J. Spitler, and D. R. Rowley Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4792 - 4801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. McAlhany, S. J. Ressler, M. Larsen, J. A. Tuxhorn, F. Yang, T. D. Dang, and D. R. Rowley Promotion of Angiogenesis by ps20 in the Differential Reactive Stroma Prostate Cancer Xenograft Model Cancer Res., September 15, 2003; 63(18): 5859 - 5865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Chauhan, A Abraham, J R A Phillips, J H Pringle, R A Walker, and J L Jones There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions J. Clin. Pathol., April 1, 2003; 56(4): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, S. J. McAlhany, F. Yang, T. D. Dang, and D. R. Rowley Inhibition of Transforming Growth Factor-{beta} Activity Decreases Angiogenesis in a Human Prostate Cancer-reactive Stroma Xenograft Model Cancer Res., November 1, 2002; 62(21): 6021 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tuxhorn, G. E. Ayala, M. J. Smith, V. C. Smith, T. D. Dang, and D. R. Rowley Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling Clin. Cancer Res., September 1, 2002; 8(9): 2912 - 2923. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
